Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | SAT1 | P21673 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24220974 | 1.00 | CYP2C19 (0.38) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL26002531 | 0.85 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL18929779 | 0.85 | OPRK1 (0.30) | — | |
| SCHEMBL22799575 | 0.85 | CYP2C19 (0.39) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL25134176 | 0.85 | CYP2C19 (0.39) | CYP2C19CYP1A2MEN1GLAKMT2A | |
| SCHEMBL21891783 | 0.83 | — | — | |
| SCHEMBL21297374 | 0.83 | KISS1R (0.39) | EPHX1 | |
| SCHEMBL16692066 | 0.83 | KISS1R (0.39) | EPHX1 | |
| SCHEMBL17662433 | 0.83 | KDM4E (0.35) | — | |
| SCHEMBL16248631 | 0.83 | KDM4E (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | STARPHARMA PTY LTD. (AU) | 2022-12-15 | — | — | US | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | CYP2C19 1908/4885CYP1A2 2337/4885MEN1 1086/4885 |
| US-20220395525-A1 | THERAPEUTIC DENDRIMER | DCK, PAICS, SAMHD1 | CYP2C19 4808/4885CYP1A2 4827/4885MEN1 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.